3-(3-tetradecylphenoxy)-1,2-propanediol | 90857-81-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-(3-tetradecylphenoxy)-1,2-propanediol
• 英文别名: 3-(3-tetradecylphenoxy)propane-1,2-diol
• CAS: 90857-81-1
• 化学式: C₂₃H₄₀O₃
• 分子量: 364.569
• InChiKey: HWTOMKWWPMCESN-UHFFFAOYSA-N

物化性质

• 沸点：
  508.3±35.0 °C(Predicted)
• 密度：
  0.978±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7.9
• 重原子数：
  26
• 可旋转键数：
  17
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(3-tetradecylphenoxy)-1,2-propanediol 在 吡啶 、 silicic acid-boric acid 作用下， 以 四氢呋喃 、 乙醚 、 Petroleum ether 为溶剂， 反应 96.0h， 生成 1-hydroxy-3-(3-tetradecylphenoxy)propan-2-yl acetate
  参考文献：
  名称：

  Analogs of platelet activating factor (PAF). 1. Some modifications of the alkoxy chain

  摘要：

  Analogues of platelet activating factor (PAF) in which the ether oxygen has been removed (6) and in which the alkoxy chain at C1 has been replaced with a o-, p-, or m-alkylphenoxy group (30, 31, and 35, respectively) have been prepared. Compound 6 shows reduced platelet aggregation and hypotensive activity in comparison with C16 and C18 PAF. The results obtained for compounds 30, 31, and 35 indicate that the hypotensive and platelet aggregating responses are sensitive to structural modification of the ether chain. The ortho analogue 30 shows no platelet aggregating activity and only a weak hypotensive response. The para analogue 31 exhibits a moderate decrease in activity in both assays. The meta analogue 35 is the most active of the three.

  DOI：

  10.1021/jm00375a016
• 作为产物：
  描述：

  4-十四烷基苯酚 在 盐酸 、 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 29.0h， 生成 3-(3-tetradecylphenoxy)-1,2-propanediol
  参考文献：
  名称：

  Analogs of platelet activating factor (PAF). 1. Some modifications of the alkoxy chain

  摘要：

  Analogues of platelet activating factor (PAF) in which the ether oxygen has been removed (6) and in which the alkoxy chain at C1 has been replaced with a o-, p-, or m-alkylphenoxy group (30, 31, and 35, respectively) have been prepared. Compound 6 shows reduced platelet aggregation and hypotensive activity in comparison with C16 and C18 PAF. The results obtained for compounds 30, 31, and 35 indicate that the hypotensive and platelet aggregating responses are sensitive to structural modification of the ether chain. The ortho analogue 30 shows no platelet aggregating activity and only a weak hypotensive response. The para analogue 31 exhibits a moderate decrease in activity in both assays. The meta analogue 35 is the most active of the three.

  DOI：

  10.1021/jm00375a016

文献信息

• Sulfur inhibitors of phospholipase A-Z
  申请人：American Cyanamid Company

  公开号：US05126291A1

  公开（公告）日：1992-06-30

  Phospholipase A.sub.2 inhibitors having the formula ##STR1## wherein R" is a C.sub.2 -C.sub.20 alkyl group, R.sub.1 " is a C.sub.1 -C.sub.4 alkyl group, y is an integer from 2 to 10, and J.sup.- is a pharmaceutically acceptable anion, are described.

  描述具有以下结构的磷脂酶A.sub.2抑制剂##STR1##其中R"是C.sub.2-C.sub.20烷基基团，R.sub.1 "是C.sub.1-C.sub.4烷基基团，y是2到10之间的整数，J.sup.-是一种药用可接受的阴离子。
• Antihypertensive phosphate derivatives
  申请人：American Cyanamid Co.

  公开号：US04762942A1

  公开（公告）日：1988-08-09

  Antihypertensive phosphate derivatives having the following formula are described: ##STR1## wherein X is selected from one or more of: (a) C.sub.1 -C.sub.24 branched or straight chain alkyl; (b) C.sub.1 -C.sub.24 branched or straight chain alkoxy; (c) ##STR2## wherein n and m are integers from 0 to 25 and the sum of n and m is less than or equal to 25; phenyl; substituted phenyl wherein the substituents are selected from the group consisting of C.sub.1 -C.sub.20 branched or straight chain alkyl, C.sub.1 -C.sub.20 branched or straight chain alkoxy, halogen, trifluoromethyl, phenyl, and substituted phenyl, phenoxy; and substituted phenoxy, wherein the substituents are selected from the group consisting of C.sub.1 -C.sub.20 branched or straight chain alkyl, halogen, trifluoromethyl, phenyl and substituted phenyl; Q is selected from the group consisting of: ##STR3## wherein R.sub.1 is selected from the group consisting of hydrogen, C.sub.1 -C.sub.4 branched or straight chain alkyl, C.sub.1 -C.sub.4 branched or straight chain alkoxy and C.sub.1 -C.sub.4 branched or straight chain alkylamino and wherein R.sub.3 is C.sub.1 -C.sub.4 alkyl, with the proviso that when Q is ##STR4## then R.sub.1 is C.sub.1 -C.sub.4 branched or straight chain alkyl; T is a bivalent radical selected from the group consisting of --(CHR).sub.p -- and ##STR5## wherein p is an integer from 1 to 15, the moiety --(CHR).sub.p -- represents an alkylene chain substituted at any position with one or more C.sub.1 -C.sub.10 alkyl groups or phenyl groups, and the moiety ##STR6## is bound with the oxygen atom attached directly to the aromatic ring; and Z is ##STR7## wherein R.sub.2 is hydrogen or C.sub.1 -C.sub.4 branched or straight chain alkyl and q is an interger from 4 to 7; in either the racemic or optically active forms.

  描述具有以下公式的抗高血压磷酸盐衍生物：##STR1##其中X从以下一个或多个中选择：(a) C.sub.1 -C.sub.24支链或直链烷基；(b) C.sub.1 -C.sub.24支链或直链烷氧基；(c) ##STR2##其中n和m是从0到25的整数，n和m的和小于或等于25；苯基；取代苯基，其中取代基选择自C.sub.1 -C.sub.20支链或直链烷基、C.sub.1 -C.sub.20支链或直链烷氧基、卤素、三氟甲基、苯基和取代苯基、苯氧基；和取代苯氧基，其中取代基选择自C.sub.1 -C.sub.20支链或直链烷基、卤素、三氟甲基、苯基和取代苯基；Q从以下一组中选择：##STR3##其中R.sub.1选择自氢、C.sub.1 -C.sub.4支链或直链烷基、C.sub.1 -C.sub.4支链或直链烷氧基和C.sub.1 -C.sub.4支链或直链烷基氨基，其中R.sub.3是C.sub.1 -C.sub.4烷基，但要注意当Q为##STR4##时，R.sub.1为C.sub.1 -C.sub.4支链或直链烷基；T是从--(CHR).sub.p --和##STR5##中选择的二价基团，其中p是从1到15的整数，基团--(CHR).sub.p --代表一个在任何位置上用一个或多个C.sub.1 -C.sub.10烷基或苯基取代的烷基链，基团##STR6##与直接连接到芳香环的氧原子结合；Z是##STR7##其中R.sub.2是氢或C.sub.1 -C.sub.4支链或直链烷基，q是从4到7的整数；可以是消旋的或光学活性形式。
• Antihypertensive phosphate derivatives and intermediates thereof
  申请人：American Cyanamid Company

  公开号：US04981989A1

  公开（公告）日：1991-01-01

  Antihypertensive phosphate derivatives having the following formula are described: ##STR1## wherein X is selected from one or more of: (a) C.sub.1 -C.sub.24 branched or straight chain alkyl; (b) C.sub.1 -C.sub.24 branched or straight chain alkoxy; (c) ##STR2## wherein n and m are integers from 0 to 25 and the sum of n and m is less than or equal to 25; phenyl; substituted phenyl wherein the substituents are selected from the group consisting of C.sub.1 -C.sub.20 branched or straight chain alkyl, C.sub.1 -C.sub.20 branched or straight chain alkoxy, halogen, trifluoromethyl, phenyl, and substituted phenyl, phenoxy; and substituted phenoxy, wherein the substituents are selected from the group consisting of C.sub.1 -C.sub.20 branched or straight chain alkyl, halogen, trifluoromethyl, phenyl and substituted phenyl; Q is selected from the group consisting of: ##STR3## wherein R.sub.1 is selected from the group consisting of hydrogen, C.sub.1 -C.sub.4 branched or straight chain alkyl, C.sub.1 -C.sub.4 branched or straight chain alkoxy and C.sub.1 -C.sub.4 branched or straight chain alkylamino and wherein R.sub.3 is C.sub.1 -C.sub.4 alkyl, with the proviso that when Q is ##STR4## then R.sub.1 is C.sub.1 -C.sub.4 branched or straight chain alkyl; T is a bivalent radical selected from the group consisting of --(CHR).sub.p -- and ##STR5## wherein p is an integer from 1 to 15, the moiety --(CHR).sub.p -- represents an alkylene chain substituted at any position with one or more C.sub.1 -C.sub.10 alkyl groups or phenyl groups, and the moiety ##STR6## is bound with the oxygen atom attached directly to the aromatic ring; and Z is ##STR7## wherein R.sub.2 is hydrogen or C.sub.1 -C.sub.4 branched or straight chain alkyl and q is an integer from 4 to 7; in either the racemic or optically active forms.

  本文描述了具有以下公式的降压磷酸酯衍生物：##STR1## 其中X从以下一个或多个中选择：(a) C.sub.1-C.sub.24支链或直链烷基；(b) C.sub.1-C.sub.24支链或直链烷氧基；(c) ##STR2## 其中n和m是0到25的整数，并且n和m的和小于或等于25；苯基；取代苯基，其中取代基被选择自由基组，该自由基组由C.sub.1-C.sub.20支链或直链烷基，C.sub.1-C.sub.20支链或直链烷氧基，卤素，三氟甲基，苯基和取代苯基组成，苯氧基；和取代苯氧基，其中取代基被选择自由基组，该自由基组由C.sub.1-C.sub.20支链或直链烷基，卤素，三氟甲基，苯基和取代苯基组成；Q被选择自由基组，该自由基组由以下组成：##STR3## 其中R.sub.1被选择自由基组，该自由基组由氢，C.sub.1-C.sub.4支链或直链烷基，C.sub.1-C.sub.4支链或直链烷氧基和C.sub.1-C.sub.4支链或直链烷基胺组成，其中R.sub.3是C.sub.1-C.sub.4烷基，但是当Q是##STR4##时，R.sub.1是C.sub.1-C.sub.4支链或直链烷基；T是选择自由基组，该自由基组由以下组成：--(CHR).sub.p--和##STR5## 其中p是1到15的整数，基团--(CHR).sub.p--表示取代任何位置具有一个或多个C.sub.1-C.sub.10烷基或苯基的烷基链，基团##STR6##与直接连接到芳香环的氧原子相结合；Z是##STR7## 其中R.sub.2是氢或C.sub.1-C.sub.4支链或直链烷基，q是4到7的整数；可以是外消旋或光学活性形式。
• Antihypertensive derivatives
  申请人：American Cyanamid Company

  公开号：US04883816A1

  公开（公告）日：1989-11-28

  Antihypertensive sulfonyl derivatives having the following formula are described: ##STR1## where R" is a C.sub.2 -C.sub.20 alkyl group, R".sub.1 is a C.sub.1 to C.sub.4 alkyl group, y is an integer from 2 to 10 and J.sup.- is a pharmocologically acceptable anion.

  本文描述了具有以下结构式的降压磺酰衍生物：##STR1## 其中R"为C.sub.2-C.sub.20烷基，R".sub.1为C.sub.1-C.sub.4烷基，y为2到10的整数，J.sup.-为药理学上可接受的阴离子。
• Analogs of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet activating factor
  作者：A. Wissner、M. L. Carroll、K. E. Green、S. S. Kerwar、W. C. Pickett、R. E. Schaub、L. W. Torley、S. Wrenn、C. A. Kohler

  DOI：10.1021/jm00087a023

  日期：1992.5

  A series of aryl phosphoglyceride (3, 19-6 1) and bis-aryl phosphate (67-135) antagonists of platelet activating factor (PAF) were prepared. A group of four bifunctional phosphorus reagents (5a-c and 7) were developed that allowed the preparation of these aryl phosphates in which the position of aromatic substitution can be varied. These compounds were examined for their ability to inhibit PAF-induced platelet aggregation of rabbit platelets. Selected compounds were also evaluated for their ability to displace [H-3]PAF from its receptor on rabbit platelets. These in vitro data were compared to similar data obtained for a number of known PAF antagonists. The compounds were evaluated in vivo, in both the mouse and rabbit, for their ability to prevent death induced by a lethal challenge of PAF. The relationships between the biological activity and the nature, lipophilicity, and position of substituents of the aromatic rings were studied. Compound 105 (CL 184005) has been selected to undergo further development as a potential therapeutic agent for the treatment of septic shock in man.